A controlled trial of natalizumab for relapsing multiple sclerosis.
By David H. Miller, O. Khan, W. Sheremata, L. Blumhardt, G. Rice, M. Libonati, A. Willmer-Hulme, C. Dalton, K. Miszkiel, P. O'Connor. New England Journal of Medicine, 2003
1,255 citations recorded by the source corpus.
Subfields: Immunology, Neurology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/aa3f391591845a3a0de176e4f8a5e872b8941ca6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Neurology
- R. Ransohoff
- Hans Lassmann
- P. Kivisäkk
- G. Kidd
- Berislav Zlokovic
- Marco Prinz
- Melissa A Brown
- Christopher K. Glass
In Pathology and Forensic Medicine
Citations in the corpus
- Of Mice and Not Men: Differences between Mouse and Human Immunology (2004, background): “In contrast, studies in mice suggested that blocking VLA-4 ( 4 1 integrin)-VCAM-1 interaction might help in MS (71) and this has indeed carried through successfully into human trials (72).”
- Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool (2011, background): “For instance, blocking the homing of T lymphocytes to the CNS using an antibody specific for α4 integrin suppresses EAE and reduces relapse rates in humans with multiple sclerosis by 66”
- Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. (2006, background): “This was a remarkable finding, and in the following years the transfer into multiple sclerosis studies using the humanized anti-VLA4 antibody natalizumab was fast and effective (Tubridy et al., 1999; Miller et al., 2003).”
- The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy (2004, background): “Other novel treatments requiring the evaluation of larger, placebocontrolled trials are estriol, [64] statins [54] and natalizumab, which is an α4 integrin antagonist [51].”
- Immunology of multiple sclerosis. (2005, neutral): “Other promising therapeutic strategies include humanized monoclonal antibodies against VLA-4 (natalizumab), which blocks BBB migration of T cells and their activation and reduces brain inflammation (349), and against the IL-2 receptor α chain (daclizumab), which activates and expands immunoregulator”